Treating Recurrent or Metastatic Endometrial Cancer with an Immunotherapy in Combination with a PARP Inhibitor or a Chemotherapy Drug identifier:
NCT02912572 (

Treatment study for metastatic endometrial cancer

Study Contact Information:

DFCI Clinical Trials Hotline: 887-338-7425
Principal Investigator: Panagiotis A Konstantinopoulos, MD
by phone: 617-632-5269 or by email 



About the Study

This study will determine the effectiveness of an immunotherapy called Avelumab, in treating recurrent or metastatic endometrial cancer. Participants will receive Avelumab, either alone or in combination with other drugs. The effectiveness of the study drugs will be measured through tumor biopsies. NOTE: This study is no longer enrolling patients.

What the Study Involves

There will be four treatment groups in this study and participants will be selected based on their tumor type.

Group 1: MSI-H and/or a POLE mutation 
This group will be open to people with one of two tumor types: MSI-H (microsatellite instability-High) and/or a POLE-mutation. MSI-H and POLE mutations are tumor markers found in some endometrial cancers. MSI-H cancers are common in people with Lynch syndrome

Group 2: MSS
This group will be open to people with a type of tumor that is MSS (microsatellite stable). 

Group 3: MSS

Group 4: MSS

This group will be open to people with a type of tumor that is MSS (microsatellite stable). 

All groups will receive the following: 

Study Locations



This Study is Open To:

People with advanced or recurrent endometrial cancer who are 18 years and older and have:

This Study is Not Open To:

People with the following are not eligible to participate:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.